Market Newsdesk

MONETT, Mo., Dec. 8, 2020 /PRNewswire/ — Jack Henry & Associates, Inc.^® (NASDAQ: JKHY) is a leading provider of technology solutions and payment processing services primarily for the financial services industry. Its Symitar^® division today announced that Texans Credit Union has selected the Episys^® core in Jack Henry’s private cloud environment.

The $1.7 billion-asset credit union decided to change core providers to improve its member services while increasing efficiencies. The credit union’s decision to outsource with Jack Henry was driven by the need to better align resources with their strategic goals. Between 7 to 12 staff members were needed to maintain its previous core. These personnel will now be able to focus on workflows and customization to ensure branch operations and processes are much more efficient. Plus, Jack Henry’s core will enable Texans to easily implement the third-party solutions of its choice.

David Frazier, president and CEO of Texans, said, “Jack Henry will provide our credit union with a strong foundation for better products and services; we look forward to making it our own through its open customization and integration tools. Having the support of a team that works hand-in-hand with our enhancements will better position us to meet the needs of our members and improve their banking experience. With the right technology and partner, we can fully focus on making our members’ financial lives easier and transactions more convenient. We now have the tools necessary to grow into the organization we want to become for our community.”

Texans’ new platform will make member service quicker, easier, and more intuitive for its front-end staff, equipping them to better meet the needs of members. Texans looks forward to unlocking the true capability of Jack Henry, such as leveraging proprietary data in both immediate ways and for future business intelligence and data-driven decisions. It all builds towards their goal of making more informed decisions when it comes to servicing their membership.

Shanon McLachlan, president of Symitar, commented, “Credit unions such as Texans recognize the importance of balancing technology with member experience. With our infrastructure and support, the credit union can customize its offerings based on their unique needs as well as those of their membership. We encourage our clients to implement the best technologies for their members and provide them with the modern platform necessary to do so with ease. Texans is a great example of a credit union that needs more independence and freedom to plan for its future, and it’s gaining that with Jack Henry.”

About Symitar 
Symitar, a division of Jack Henry & Associates, Inc.^®, is the leading provider of integrated computer systems for credit unions of all sizes. Symitar has been selected as the primary technology partner by more than 800 credit unions, serving as a single source for integrated, enterprise-wide automation and as a single point of contact and support. Additional information is available at www.symitar.com. 

About Jack Henry & Associates

Jack Henry (NASDAQ:JKHY) is a leading provider of technology solutions primarily for the financial services industry. We are a S&P 500 company that serves approximately 8,700 clients nationwide through three divisions: Jack Henry Banking^® supports banks ranging from community banks to multi-billion-dollar institutions; Symitar^® provides industry-leading solutions to credit unions of all sizes; and ProfitStars^® offers highly specialized solutions to financial institutions of every asset size, as well as diverse corporate entities outside of the financial services industry. With a heritage that has been dedicated to openness, partnership, and user centricity for more than 40 years, we are well-positioned as a driving market force in future-ready digital solutions and payment processing services. We empower our clients and consumers with the human-centered, tech-forward, and insights-driven solutions that will get them where they want to go. Are you future ready? Additional information is available at www.jackhenry.com. 

Statements made in this news release that are not historical facts are forward-looking information.  Actual results may differ materially from those projected in any forward-looking information.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated by any forward-looking information.  Additional information on these and other factors, which could affect the Company’s financial results, are included in its Securities and Exchange Commission (SEC) filings on Form 10-K, and potential investors should review these statements.  Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from any forward-looking information.

JKHY-SY 

View original content:http://www.prnewswire.com/news-releases/texans-credit-union-selects-symitar-for-a-modern-fully-supported-core-301188106.html

SOURCE Jack Henry & Associates, Inc.

SHANGHAI, Dec. 8, 2020 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the adalimumab biosimilar HLX03, developed and manufactured by the Company independently, has been approved by the National Medical Products Administration (NMPA) for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS) and plaque psoriasis (Ps). It is the third monoclonal antibody (mAb) developed by Henlius and approved in China, after the Company’s rituximab biosimilar HLX01, the first China-developed biosimilar, and trastuzumab biosimilar HLX02 (EU brand name Zercepac), the first China-developed mAb biosimilar approved both in China and in the EU. HLX03 is also Henlius first product approved for the treatment of autoimmune diseases. Its successful development is based on the integrated biopharmaceutical platform of Henlius.

During the development process of HLX03, Henlius strictly followed the NMPA biosimilar guidelines and has taken multiple head-to-head comparisons between HLX03 and the reference adalimumab. Results from analytical studies, non-clinical studies and clinical studies showed that HLX03 is highly similar to the reference adalimumab in terms of quality, safety and efficacy. Henlius has reached an agreement with Wanbang Biopharma (Wanbang), which is a subsidiary of Fosun Pharma and has been deeply engaged in the field of rheumatology for many years. Under the agreement, Wanbang will be responsible for the commercialization of HLX03 in China.

Mr. Wenjie Zhang, Chief Executive Officer and President of Henlius, said, “The approval of this product marks the expansion of the Company’s commercial pipeline into the field of autoimmune diseases and the scope of patients that can benefit from Henlius products is further broadened. Henlius will continue optimizing and upgrading the product, and cooperating with Wanbang Biopharma to promote the commercialization of HLX03, so as to bring high-quality treatment options to patients suffering from autoimmune diseases.”

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with a focus on oncology, autoimmune diseases and ophthalmic diseases. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialisation. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies and has continued to explore immuno-oncology combination therapies with proprietary HLX10 (anti-PD-1 mAb) as backbone. Products have been licensed out to nearly 100 countries and regions.

View original content:http://www.prnewswire.com/news-releases/henlius-adalimumab-biosimilar-approved-by-nmpa-301187891.html

SOURCE Henlius

Envirocleanse-A disinfectant is non-toxic, enviro-friendly and kills COVID-19 virus;

Candid Clean sanitizer is gentle on skin and keeps hands protected

VANCOUVER, BC, Dec. 8, 2020 /PRNewswire/ – Maitri Health Technologies Corp. (“Maitri”) (CSE: MTEC), a global platform for healthcare supply security, announces the availability of Envirocleanse-A disinfectant and Candid Clean sanitizer. The cleaning and safety solutions are both Health Canada-certified and help expand Maitri’s personal protective equipment (PPE) offering and product platform.

Envirocleanse-A, a subsidiary of Charter Brokerage a Berkshire Hathaway company, is a commercial disinfectant, registered with the Environmental Protection Agency (EPA) and Health Canada to kill SARS-CoV-2, the novel coronavirus that causes COVID-19.  Envirocleanse-A is 100 times more effective than bleach, yet is non-toxic, biodegradable and does not require masks, gloves or other safety equipment to apply – it’s harmless to humans, animals and the environment and is Federal Drug Administration (FDA) acknowledged to be safe and effective for use directly on food and food contact surfaces. Maitri has partnered with CleanTerra Services Ltd. to supply the product both Nationally and Internationally. 

“We were very selective in choosing a disinfectant for our product platform,” said Andrew Morton, CEO of Maitri. “Many cleaning products are corrosive and damaging to tables, chairs, counters or other surfaces, and worse, potentially dangerous for users and the environment. Other disinfectants are complicated to mix or dilute. Envirocleanse-A eliminates all those issues.”

CleanTerra is ideal for industries where high-traffic and high-touch surfaces require diligent disinfecting – tourism and hospitality; airlines and public transit, restaurants, bars and entertainment; retail; healthcare and education; fitness facilities, and private sector office and commercial operations.

Maitri also announces the availability of Candid Clean, a Canadian-made, 75%-Isopropanol-based spray hand sanitizer. Candid Clean evaporates quickly, does not dry out hands and comes in a variety of scents. It also has shelf life of three years.

“Hand sanitizer is a key part of a safety routine and we’re pleased to offer a superior solution that people will want to use. Candid Clean is gentle on the hands and strong enough to be used as a disinfectant,” said Morton.

These new disinfectant and sanitizer solutions join Maitri’s 3D facial masks and Win-Shield face shields in the Company’s comprehensive suite of domestically-manufactured PPE. The 3D family of masks offer a selection of certified surgical masks, and the innovative Win-Shield™ face shield features a patent-pending design and additional personal protection.

About Maitri Health Technologies
Maitri Health Technologies Corp. (CSE: MTEC) is a global platform for healthcare supply security. Our mission is to enhance safety and quality of life, and keep organizations and economies running. Maitri provides a reliable source of innovative, certified personal protective equipment (PPE) and testing solutions through an onshore manufacturing model. Our stable, scalable supply chain is integrated with unique digital technology to deliver a comprehensive healthcare supply platform. For more information: https://maitrihealth.ca/

For more information: [email protected]

On behalf of the board of directors,
MAITRI HEALTH TECHNOLOGIES CORP.
Andrew Morton, Chief Executive Officer

Forward-Looking Statements
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

View original content to download multimedia:http://www.prnewswire.com/news-releases/maitri-health-technologies-adds-certified-disinfectant-and-sanitizer-to-global-healthcare-supply-platform-301188007.html

SOURCE Maitri Health Technologies Corp.

PHOENIX, Dec. 8, 2020 /PRNewswire/ — Harvest Health & Recreation Inc.  (“Harvest”) (CSE: HARV, OTCQX: HRVSF), a vertically integrated cannabis company and multi-state operator in the U.S., today announced the retirement of Chief Operating Officer Ronald Goodson, effective December 31, 2020.

Harvest has no immediate plans to fill the Chief Operating Officer position. The responsibilities held by Ron Goodson will be assumed by other members of Harvest’s senior leadership team.  “We thank Ron for his service over the past year and wish him all the best in his retirement,” said Chief Executive Officer Steve White. 

About Harvest Health & Recreation Inc.

Headquartered in Tempe, Arizona, Harvest Health & Recreation Inc. is a vertically integrated cannabis company and multi-state operator. Since 2011, Harvest has been committed to expanding its retail and wholesale presence throughout the U.S., acquiring, manufacturing, and selling cannabis products for patients and consumers in addition to providing services to retail dispensaries. Through organic license wins, service agreements, and targeted acquisitions, Harvest has assembled an operational footprint spanning multiple states in the U.S. Harvest’s mission is to improve lives through the goodness of cannabis. We hope you’ll join us on our journey:


https://harvesthoc.com


 

Facebook: 

@HarvestHOC


Instagram: 

@HarvestHOC


Twitter: 

@HarvestHOC 

Forward-looking Statements

This press release contains statements which constitute “forward-looking information” within the meaning of Canadian and U.S. securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Harvest with respect to future business activities. Forward-looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) expectations regarding the size of the U.S. cannabis market, (ii) the ability of Harvest to successfully achieve its business objectives, (iii) plans for expansion of Harvest, and (iv) expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects Harvest management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Harvest believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the effects of the weather, natural disasters, and health pandemics, including the novel coronavirus (COVID-19), on customer demand, Harvest’s supply chain as well as its consolidated results of operation, financial position and cash flows, the ability of Harvest to develop Harvest’s brand and meet its revenue, growth and profitability objectives, the ability of Harvest to locate and execute acquisitions of companies, properties or assets that are accretive to its revenue and business objectives, the ability of Harvest to obtain and/or maintain licenses or other contractual rights to operate in the jurisdictions in which it operates or in which it expects or plans to operate; adverse decisions in litigation or arbitrations we are currently involved in and additional litigation
 or arbitration
 in which it may be involved in the future
; changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of Harvest to raise debt and equity capital in the amounts needed and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that Harvest operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws, including those related to taxation; and increasing costs of compliance with extensive government regulation.
 These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. Although Harvest has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Forward-looking information contained in this press release is based on Harvest’s current estimates, expectations and projections, which Harvest believes are reasonable as of the current date. Harvest can give no assurance that these estimates, expectations and projections will prove to have been correct. You should not place undue reliance on forward-looking statements, which are based on the information available as of the date of this press release. Forward-looking statements contained in this press release are made of the date of this press release and, except as required by applicable law, Harvest assumes no obligation to update or revise them to reflect new events or circumstances. Historical statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by Harvest. In particular historical results should not be taken as a representation that such trends will be replicated in the future. No statement in this press release is intended to be a profit forecast. While the information contained herein is believed to be accurate, Harvest, its affiliates, and their respective stockholders, members, partners, directors, managers, officers, employees, agents, advisors, and other representatives each expressly disclaims any and all liability for representations, expressed or implied, contained in or omitted from this press release or any other written or oral communications transmitted to any interested party in the course of its evaluation of Harvest. Nothing contained herein is or shall be relied upon as a promise or representation by Harvest or their affiliates or any of their respective stockholders, members, partners, directors, managers, officers, employees, agents, advisors, or other representatives as to the past or future performance of Harvest. Only those particular representations and warranties made by Harvest in a written definitive agreement, when and if one is executed, and subject to such limitations and restrictions as may be specified in such agreement, shall have any legal effect
.

This forward-looking information may be affected by risks and uncertainties in the business of Harvest and market conditions.
Please see the heading “Risk Factors” in our Canadian filings, and the heading “Item 1A. Risk Factors” in our Form 10, filed with the U.S. Securities and Exchange Commission on November 5, 2020, and subsequent amendments thereto, as well as our subsequent filings in the United States and Canada, for a discussion of material risk factors that could cause actual results to differ materially from the forward-looking information.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Harvest has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Harvest does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/harvest-health–recreation-inc-announces-retirement-of-chief-operating-officer-ron-goodson-301187892.html

SOURCE Harvest Health & Recreation Inc.

• EMA has endorsed iX Biopharma’s proposed Phase 3 clinical development programme for Wafermine™
• EMA Scientific Advice provides clarity on registration pathway in Europe

SINGAPORE, Dec. 8, 2020 /PRNewswire/ — Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (“iX Biopharma” or, “the Company”) is pleased to announce that it has received positive feedback from the European Medicines Agency (EMA) in its scientific advice to the Company regarding its Phase 3 clinical development programme for Wafermine™, its sublingual ketamine wafer, for registration in Europe (the “EMA Scientific Advice”).

In the EMA Scientific Advice, the EMA endorsed the Company’s proposed design of the pivotal Phase 3 studies. The Phase 3 programme, which has been similarly agreed by the US FDA, consists of two randomised, double blind, placebo controlled studies, one in an orthopaedic pain model (bunionectomy) and one in a soft-tissue pain model (abdominoplasty). The primary efficacy measure for both studies will be SPID12, which is the summed pain intensity difference over 12 hours. The summed pain intensity difference over 24 hours (SPID24) and 48 hours (SPID48) will be evaluated as secondary endpoints. The Phase 3 studies will use the same pain models and primary endpoint that was successfully evaluated in Wafermine™’s Phase 2b clinical study.

With the successful outcome of the EMA Scientific Advice and End-of-Phase 2 meeting with the US FDA, the Company has now reached consensus with the regulators of the major markets of Europe and the United States on the remaining clinical development required to support the approval of Wafermine™ for the treatment of acute moderate to severe pain in those markets.

Dr. Janakan Krishnarajah, Chief Operating Officer and Chief Medical Officer of iX Biopharma said:
“EMA’s endorsement of the proposed Phase 3 programme design is an exciting achievement that affirms the robustness of our clinical development approach. The EMA response confirms that our development strategy will satisfy the clinical study requirements for both US and European approval, and provides clarity to programme cost and timelines. This makes Wafermine™ a very attractive late stage partnering opportunity for both US and European markets.“

For more information on Wafermine™, please refer to the link below:
[https://www.ixbiopharma.com/wafermine]

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

Contact for media
:

Dr Janakan Krishnarajah
Chief Operating Officer and Chief Medical Officer
T: +65 6235 2270
E: [email protected]

Investor Relations:
Eva Tan
Director, Corporate and Commercial Strategy
T: +65 6235 3212
E: [email protected]

Kamal Samuel/Ngo Yit Sung/Jonathan Wee
T: +65 6438 2990
E: [email protected]

View original content:http://www.prnewswire.com/news-releases/ix-biopharma-receives-positive-ema-scientific-advice-for-waferminetm-301187988.html

SOURCE iX Biopharma Ltd

LONDON, Dec. 8, 2020 /PRNewswire/ — Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the introduction of RI.INSIGHTS, the first platform designed to enable orthopaedic surgeons to benchmark robotics surgical experiences with other users to optimize surgical planning and improve patient reported outcome measures (PROMs).

Previously, surgeons were unable to review complex robotics surgical information for individual patients or benchmark against their peers. RI.INSIGHTS collects intra and post-op data during robotics-assisted procedures and then presents this data alongside post-op patient outcomes allowing surgeons to gain insights of their robotics-assisted surgical procedures.

The RI.INSIGHTS platform is a key addition to Smith+Nephew’s Real Intelligence portfolio of products and solutions – including the CORI™ Surgical System – introduced earlier this year.

“The launch of RI.INSIGHTS further strengthens Smith+Nephew’s Real Intelligence  platform and underscores our advancement into digital health,” said Skip Kiil, President of Global Orthopaedics for Smith+Nephew. “We are excited for surgeons to start using the insights provided by strong clinical data collected by the platform to drive improved patient outcomes.”

“The RI.INSIGHTS platform maps the future of robotics and digital surgery,” said Dr. Nathwani, Consultant Orthopedic Surgeon, Imperial College Healthcare, NHS Trust and The London Clinic. “Robotics has proven accuracy, and using the wealth of individualized intra and post-op planning data that RI.INSIGHTS delivers, we can analyse surgical parameters like never before to provide the best customized robotic solutions for our patients.”

“Today, with RI.INSIGHTS we can streamline robotics surgery with proven accuracy, where the data I collect as a surgeon can drive my surgical decisions before making a bone cut. Additionally, the outcomes data collected after the surgery provides a feedback loop that can validate those surgical decisions, allowing us to further refine our surgical goals,” said Dr. Jimmy Chow, Orthopaedic Surgeon for Hip and Knee, Orthopedic Institute of the West. “Tomorrow, we hope to be able to change the shape of orthopedics through data. The RI.INSIGHTS platform is sophisticated enough to one day identify, qualify, and even guide future surgeons’ decisions. We hope to elevate the level of all surgeries and outcomes for all patients.”

RI.INSIGHTS is available on a limited basis, with a full commercial release following in 2021. To learn more about Smith+Nephew’s Real Intelligence ecosystem, please visit www.smith-nephew.com/professional/products/robotics/real-intelligence/.

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,500+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

Forward-looking Statements


This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

™ 
Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

View original content to download multimedia:http://www.prnewswire.com/news-releases/smithnephew-announces-riinsights—a-global-data-analytics-platform-designed-to-advance-the-standard-of-care-for-robotics-assisted-joint-replacement-procedures-301188028.html

SOURCE Smith & Nephew plc

SISTERS, Ore., Dec. 8, 2020 /PRNewswire/ — Laird Superfood (NYSE American: LSF), creator of assorted plant-based superfood products, is launching its new ACTIVATE Prebiotic Daily Greens supplement to support gut health. Prebiotics are reported to ferment in the lower intestine and provide fuel for vital gut flora.*

The new plant-based ACTIVATE Prebiotic Daily Greens is formulated with powerful superfood fruits and vegetables chosen for their positive influence on the gut microbiome – which is vital to overall gut health.* Each ingredient was hand-selected by Laird Superfood’s team of nutritionists and naturopathic doctors in partnership with Company Co-founders Laird Hamilton and his wife Gabby Reece.

“A happy gut is the foundation of happy health – a fact backed up by emerging science and extensive research,” said Gabby Reece, chief brand ambassador of Laird Superfood. “In keeping with our company mantra, Better Food, Better You, we wanted to create a product that nourishes and supports the gut microbiome. Our ACTIVATE Prebiotic Daily Greens is jam-packed with powerful superfoods, including the special ingredient Shilajit, an organic plant matter that Laird has been wanting to include in our products for years. It is commonly used in ayurvedic medicine for its positive effect on well-being.”   

A perfect addition to any consumer’s daily ritual, the ACTIVATE Prebiotic Daily Greens features a blend of 18 ingredients including fruits and vegetables with naturally occurring polyphenols and prebiotic dietary fiber that naturally support the gut.* Functional Mushrooms and Shilajit round out this superfood blend. Shilajit is a sticky substance found primarily in the rocks of the Himalayas and is comprised of important nutrients like fulvic acid and other minerals. Each serving of the Prebiotic Daily Greens has the equivalent of 14 kale leaves, 4 spinach leaves, 1 broccoli floret, and 5 blueberries. 

As is the case with all Laird Superfood products, ACTIVATE Prebiotic Daily Greens contains no artificial ingredients, no preservatives, and is Non-GMO. Supplying a good source of fiber (four grams of fiber per serving) and Vitamin C, Laird Superfood’s ACTIVATE Prebiotic Daily Greens supports gut microbiome which is critical for gut health.* 

The fresh green taste of ACTIVATE Prebiotic Daily Greens is complemented by blueberry, acai, lemon, and blends nicely into smoothies, protein shakes, or can be consumed simply by mixing into water or with other supplement mixes. Laird Superfood’s ACTIVATE Prebiotic Daily Greens is available at lairdsuperfood.com for $19.95 for a 4.2 oz bag. 

About Laird Superfood


Laird Superfood, Inc. creates award-winning, plant-based superfood products that are both delicious and functional. Known for its highly popular coffee creamers, hydration products, supplements, roasted and instant coffees, teas, hot chocolate, and harvest snacks, the Company’s products are designed to enhance your daily ritual and keep consumers fueled naturally throughout the day. The Company was co-founded in 2015 by the world’s most prolific big-wave surfer, Laird Hamilton. Laird Superfood’s offerings are environmentally conscientious, responsibly tested, and made with real ingredients. Shop all products online at lairdsuperfood.com and join the Laird Superfood community on social media for the latest news and daily doses of inspiration.

View original content to download multimedia:http://www.prnewswire.com/news-releases/laird-superfood-introduces-activate-prebiotic-daily-greens-for-gut-microbiome-support-301187889.html

SOURCE Laird Superfood

ST. PAUL, Minn., Dec. 8, 2020 /PRNewswire/ — A tech challenge to invent a better way to track polar bears is moving out of the lab and into the Arctic. Wild polar bears are testing out new prototypes created by 3M scientists through a voluntary Polar Bears International (PBI) challenge. The pilot tags are non-permanent and combine currently available satellite transmitters with innovative ways to attach them.

“Traditionally, scientists have used satellite collars to follow polar bears, but the collars can only be placed on adult females,” said Geoff York, senior director of conservation at Polar Bears International. “Adult males can’t be collared because their necks are as wide as their heads, and young bears grow too quickly to be safely collared. As transmitters have become smaller researchers have tested GPS ear tags and implants. But ear tags must be permanently attached, and implants require minor surgery. The devices designed by 3M represent a major potential step forward—they could be used on all classes of polar bears and would allow us to obtain critical data with the least impact possible.”

Researchers study polar bears behavior in the Arctic to better understand movement patterns and habitat use while collecting other data. But scientists are always looking for ways to improve existing technology and make research less invasive. In this case, the challenge was to create a way to attach a tracking device to a polar bear’s fur.

Four new prototype polar bear tracker tags are being tested on polar bears in Western Hudson Bay in the far north of Manitoba, Canada, and will later be tested in zoos that routinely conduct research to benefit conservation. The prototype tags are non-toxic, temporary and attach only to the bear’s fur.

“I am tremendously excited to take this science out of the lab and into the Arctic on wild polar bears. This challenge really exemplifies the collaborative spirit, science and creativity that drives innovation at 3M,” said Jon Kirschhoffer, an advanced research specialist in the 3M Corporate Research Systems Lab.  “We are proud to help support Polar Bears International’s work in studying polar bears.”

Jon’s son BJ Kirschhoffer is director of field operations at Polar Bears International. He grew up knowing about how 3M applies science to solve all sorts of problems.  Thus, PBI came to 3M to see if its scientists could help develop a solution.

“I asked my dad if the 3M technical community could figure out how to stick a tag on a polar bear, and they rose to the challenge,” BJ said. “They liked the environmental aspect of it and the chance to contribute to polar bear conservation.”

The prototypes range from mechanical solutions to adhesive solutions and some were a little bit of everything. Some of the concepts utilized existing 3M technologies and some ideas were completely new. All need to be able to withstand the usual: extreme cold, snow, saltwater, and some polar-bear specific actions: rolling in the snow, for example. The “burr on fur” approach allows the device to latch onto and “stick” to a polar bear’s fur.

While not involved in this project, Dr. Megan Owen, corporate director of wildlife conservation science for San Diego Zoo Global, is excited about the prospects. “The Burr on Fur project could provide a real breakthrough in how we track wildlife,” she said. “It’s an exciting innovation that could go well beyond polar bears to help us study species from leopard to giraffe.”

Polar Bears International is testing the prototypes as part of ongoing tagging and tracking work on the Western Hudson Bay polar bear subpopulation in collaboration with the University of Alberta and Dr. Andrew Derocher. In addition to tags helping partners track the bears for research, improved tagging technology may provide opportunities to better warn communities of approaching bears in the event they return to Churchill or move towards communities further North.

Polar Bears International also plans to test tags on zoo bears, working with zoo and aquarium partners in their Arctic Ambassador Center network. Zoo bears serve as ambassadors for their wild cousins and enable scientists to conduct research that would not otherwise be possible.  In the case of the tags, deploying them on zoo bears will enable researchers to closely monitor how they perform under various conditions.

“This is a significant moment for polar bear research and conservation,” said Krista Wright, executive director or Polar Bears International. “As the Arctic continues to warm and sea ice melts, creative and innovative advances in research methods and technology are critical to furthering conservation efforts—for polar bears and for wildlife around the globe.” 

Polar Bears International wishes to thank the Point Defiance Zoo and Aquarium’s Dr. Holly Reed Conservation Fund and the Kansas City Zoo for help with funding.

About Polar Bears International

Polar Bears International’s mission is to conserve polar bears and the sea ice they depend on. Through media, science, and advocacy, we work to inspire people to care about the Arctic, the threats to its future, and the connection between this remote region and our global climate. PBI is the only nonprofit organization dedicated solely to wild polar bears and Arctic sea ice, and our staff includes scientists who study wild polar bears. The organization is a recognized leader in polar bear conservation. For more information, visit www.polarbearsinternational.org.
PBI Contacts: Annie Edwards, [email protected] and Melissa Hourigan, [email protected], 720-608-1919.

About 3M

At 3M (NYSE: MMM), we apply science in collaborative ways to improve lives daily. Our 96,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at www.3M.com or on Twitter @3M or @3MNews.

3M Contact: Jennifer Ehrlich[email protected]  651-736-9430

View original content to download multimedia:http://www.prnewswire.com/news-releases/bear-necessity-polar-bears-test-new-tracking-tech-invented-in-polar-bears-international3m-tech-partnership-301187900.html

SOURCE 3M

SAN JOSE, Calif., Dec. 8, 2020 /PRNewswire/ — eBay, one of the world’s largest online marketplaces, is introducing a low cost way for sellers to securely ship trading cards. Beginning January 2021, the new shipping service, eBay standard envelope, allows sellers in the U.S. to print labels and ship trading cards priced $20 and under and up to 3 oz., in an envelope with tracking included, for less than $1.

“eBay has been a trusted leader in the collectibles business for nearly 25 years, and we are continually working to deliver enhancements that meet the needs of our sellers,” said Nicole Colombo, Head of Collectibles at eBay. “Our hope is that eBay standard envelope will allow sellers to make more money on low-priced single cards and allow them to meet our shipment tracking standards.”

Trading cards on the rise
Recent eBay data shows that collecting and selling trading cards is a continuously growing hobby. Compared to just five years ago, trading cards sales have risen almost 300 percent on eBay. In 2020 alone, eBay has sold over 45 million trading cards. This new shipping service will benefit the millions of buyers and sellers growing their sports and non-sports trading cards collections on the marketplace.

As affordable as a stamp, with extra perks included
In addition to great savings on shipping, eBay standard envelope has the following benefits when buying and selling:

• 
  Cost-effective Shipping Method:
  
   eBay standard envelope will cost less than $1, with savings up to 70% over USPS First Class Package Service shipping costs, plus includes shipping protection.
• 
  Ship items with ease:
   Once the item sells, sellers simply print the label using eBay Labels and hand-off their shipment to USPS.
• 
  Avoid lost items or items not received:
  Many sellers simply use postage stamps for low-priced trading cards, which doesn’t provide tracking. With eBay standard envelope’s included tracking, buyers and sellers can rest assured their trading cards are going to the right place, without hassle or complications.
• 
  Top Rated Seller Status:
   With integrated tracking, sellers can now qualify for eBay’s Top Rated Status along with the 10 percent discount, badging and additional eBay protections.
• 
  Larger Seller Inventory: eBay standard envelope makes it easier to make money on sales of low-priced single cards in addition to high-value cards.

The beta launch for the new shipping service will be available January 2021 for sellers in the U.S. with plans to expand to new categories in the future.

About eBay
eBay Inc (NASDAQ: EBAY) is a global commerce leader including the Marketplace and Classifieds platforms. Collectively, we connect millions of buyers and sellers around the world, empowering people and creating opportunity for all. Founded in 1995 in San Jose, California, eBay is one of the world’s largest and most vibrant marketplaces for discovering great value and unique selection. For more information about the company and its global portfolio of online brands, visit www.ebayinc.com.            

View original content to download multimedia:http://www.prnewswire.com/news-releases/ebay-introduces-more-affordable-shipping-solution-for-selling-trading-cards-20-and-under-301188323.html

SOURCE eBay Inc.

CHARLOTTE, N.C., Dec. 8, 2020 /PRNewswire/ — NN, Inc., (NASDAQ: NNBR) a diversified industrial company, today announced that Jeri Harman has been named Board Chairman, effective January 4, 2021. She will succeed Robert Brunner, who will continue to serve on NN’s Board as a Director.

Mr. Brunner commented, “NN’s recently completed strategic transformation has enabled the Company to begin a new stage as a financially strengthened organization, better positioned to compete globally in industrials end markets. I look forward to continuing to support NN through this next phase of growth as a Director, and I am confident that under Jeri and the management team’s leadership, NN will further advance its strategic growth plans and create long-term value for all stakeholders.”

Warren Veltman, President & Chief Executive Officer, added, “Over the past three years as Chairman, Bob has been instrumental as we implemented our strategic transformation, and I am looking forward to continuing to work alongside him in the Director capacity. As the Company continues to build upon the progress made, Jeri’s leadership and deep financial knowledge will be invaluable as we continue our efforts to best position the Company for success.”

Ms. Harman was appointed to the NN Board of Directors in February 2019, bringing extensive capital markets knowledge and more than 30 years of financing experience to her role. Her strategic insights and financial expertise helped guide NN throughout the strategic review process, which culminated in the Company’s sale of its Life Sciences division in October. Ms. Harman is Founder & Chairman of Avante Capital Partners, a women and minority-owned private credit and structured equity fund. She has served on numerous boards over her career, and in addition to her role on NN’s Board, currently serves on the board of Engineered Performance Technologies, a consumer-focused automotive aftermarket performance products company.

Ms. Harman commented, “I am honored to be appointed Chairman of NN’s Board. Bob’s leadership has been influential in creating the more nimble and focused organization that NN is today, and I look forward to continuing to work closely with him, the Board and NN leadership to continue building on our collective efforts to strengthen NN’s position as a leading diversified industrial company.”

In addition, the Company announced that Directors David Floyd and Steven Warshaw will be stepping down from NN’s Board of Directors. Mr. Floyd, a member of the Board since 2016, will retire from the Board effective January 4, 2021. Mr. Warshaw, a member of the Board since 1997, will retire from the Board and not seek reelection at the 2021 Annual Stockholders Meeting. Effective January 4, 2021, Raynard Benvenuti will serve as Chair of the Compensation Committee and Christina Carroll will serve as Chair of the Governance Committee. Mr. Benvenuti and Ms. Carroll will continue to serve as members of the Audit Committee.

Mr. Brunner continued, “We want to thank both David and Steven for their service to NN’s Board of Directors. David’s deep knowledge of the medical technology industry was instrumental as we built out the Life Sciences business over the last several years, culminating in the sale of the business this past October. Steven’s trusted guidance over two decades and his collective contributions have made a significant and lasting impact on NN.”

The Board of Directors has established a search committee that will initiate a process to replace both Director seats.

NN, Inc., a diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has 30 facilities in North America, Europe, South America, and China.

Except for specific historical information, many of the matters discussed in this press release may express or imply projections of revenues or expenditures, statements of plans and objectives or future operations or statements of future economic performance. These, and similar statements, are forward-looking statements concerning matters that involve risks, uncertainties and other factors which may cause the actual performance of NN, Inc. and its subsidiaries to differ materially from those expressed or implied by this discussion. All forward-looking information is provided by the Company pursuant to the safe harbor established under the Private Securities Litigation Reform Act of 1995 and should be evaluated in the context of these factors. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “assumptions”, “target”, “guidance”, “outlook”, “plans”, “projection”, “may”, “will”, “would”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “potential” or “continue” (or the negative or other derivatives of each of these terms) or similar terminology. Factors which could materially affect actual results include, but are not limited to: general economic conditions and economic conditions in the industrial sector, the impacts of the coronavirus (COVID-19) pandemic on the Company’s financial condition, business operations and liquidity, inventory levels, regulatory compliance costs and the Company’s ability to manage these costs, start-up costs for new operations, debt reduction, competitive influences, risks that current customers will commence or increase captive production, risks of capacity underutilization, quality issues, availability and price of raw materials, currency and other risks associated with international trade, the Company’s dependence on certain major customers, and the successful implementation of the global growth plan including development of new products. Similarly, statements made herein and elsewhere regarding pending and completed transactions are also forward-looking statements, including statements relating to the future performance and prospects of an acquired business, the expected benefits of an acquisition on the Company’s future business and operations and the ability of the Company to successfully integrate recently acquired businesses.

For additional information concerning such risk factors and cautionary statements, please see the section titled “Risk Factors” in the Company’s periodic reports filed with the Securities and Exchange Commission, including, but not limited to, the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and when filed, the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2020. Except as required by law, we undertake no obligation to update or revise any forward-looking statements we make in our press releases, whether as a result of new information, future events or otherwise.

View original content:http://www.prnewswire.com/news-releases/nn-inc-announces-changes-to-board-of-directors-301187875.html

SOURCE NN, Inc.